Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  ImmunoCellular Therapeutics Ltd    

 SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2016 1,50 M
EBIT 2016 -21,5 M
Net income 2016 -20,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 4,30 M
EBIT 2017 -19,8 M
Net income 2017 -21,2 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 5,28x
Capi. / Sales2017 1,84x
Capitalization 7,92 M
More Financials
Company
ImmunoCellular Therapeutics Ltd. is a Los Angeles-based clinical-stage company that develops immune-based therapies for the treatment of brain and other cancers.ImmunoCellular's pipeline includes: ICT-121, a dendritic cell immunotherapy targeting the CD133 antigen on stem cells in recurrent... 
More about the company
Latest news on IMMUNOCELLULAR THERAPEUTIC
01/12 IMMUNOCELLULAR THERAPEUTICS LTD : Latest Reports on ImmunoCellular Therapeutics ..
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Change in Directors or Principal Officers, O..
2016 IMMUNOCELLULAR THERAPEUTICS : Announces Management Changes
2016 IMMUNOCELLULAR THERAPEUTICS : Research Reports Initiation on Biotech Stocks -- C..
2016 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
2016 IMMUNOCELLULAR THERAPEUTICS : Reports Updated Immune Monitoring Data from ICT-10..
2016 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
2016 IMMUNOCELLULAR THERAPEUTICS LTD : REVERSE SPLIT: 1 of 40
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Amendments to Articles of Inc. or Bylaws; Ch..
2016 IMMUNOCELLULAR THERAPEUTICS, LTD. : Results of Operations and Financial Conditio..
More news
Sector news : Biotechnology & Medical Research - NEC
01/13DJNOVARTIS : Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
01/12 Investors in big pharma, biotech look to ride out Trump storm
01/12DJHot Stocks to Watch in the U.S. and Canada
01/10 Regeneron CEO says Amgen not putting patients first in patent dispute
01/09DJCELGENE : Anticipates Slowing Sales Growth for Main Drug Revlimid
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q3 2016 Results - Ea..
2016 ImmunoCellular Therapeutics EPS in-line
2016 ImmunoCellular Therapeutics' (IMUC) CEO Andrew Gengos on Q2 2016 Results - Ea..
2016 ImmunoCellular Therapeutics beats by $0.01
2016 ImmunoCellular's late-stage study of lead product candidate in glioblastoma c..
Advertisement
Chart IMMUNOCELLULAR THERAPEUTIC
Duration : Period :
ImmunoCellular Therapeutic Technical Analysis Chart | US4525361055 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 1
Average target price -
Spread / Average Target -100%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Anthony J. Gringeri President, Chief Executive Officer & Director
Gary S. Titus Chairman
David E. Fractor Principal Financial & Accounting Officer
Steven J. Swanson Senior Vice President-Research
John S. Yu Secretary & Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOCELLULAR THERAPE..797.83%8
INCYTE CORPORATION17.10%22 120
QUINTILES IMS HOLDINGS..-0.26%18 673
CELLTRION, INC.--.--%10 581
LONZA GROUP AG4.03%9 711
ALKERMES PLC0.29%8 471
More Results